Expanding Applications Beyond Kidney Disease
While chronic kidney disease remains a primary indication, the Erythropoietin Drugs Market extends to various medical conditions. Patients with HIV therapy-related anemia and certain autoimmune disorders also benefit from erythropoietin treatment.
Emerging research explores potential neuroprotective properties of erythropoietin in neurological disorders. Although still under investigation, these possibilities highlight the hormone’s broader biological impact.
As scientific understanding deepens, additional therapeutic applications may emerge, expanding the scope of erythropoietin-based interventions.
2 Views